Alterme vs Ozempic: Comparison Guide

Alterme vs Ozempic: A Comparison Guide

If you are comparing Alterme and Ozempic, the biggest question is usually whether they are different medicines or two versions of the same core therapy. In India, that distinction matters because the brand, device, local availability, and approved indications can all shape what your clinician recommends.

This guide offers a clear, practical comparison of Alterme and Ozempic so you can ask better questions at your next appointment. Consult your healthcare provider before starting any medication.

What is Ozempic?

Ozempic is Novo Nordisk’s brand name for semaglutide, a GLP-1 receptor agonist used in adults with type 2 diabetes and also widely discussed because semaglutide can reduce appetite and support weight loss in some people.

Semaglutide works by helping regulate blood sugar, slowing gastric emptying, and increasing feelings of fullness. Ozempic is supplied in a pre-filled pen and is taken once weekly under clinician guidance.

What is Alterme?

Alterme is a semaglutide brand associated with Zydus in India. Zydus announced Alterme alongside its other semaglutide brands for the Indian market, using a reusable pen platform designed to support different dose strengths.

In this context, Alterme is being discussed as a branded semaglutide option in India rather than as a pharmacy-mixed alternative.

What do they have in common?

The most important similarity is the active ingredient. Both Alterme and Ozempic are built around semaglutide, so the core mechanism is the same.

Both are part of the GLP-1 class and are used within a broader treatment plan that may include:

• dietary changes
• regular physical activity
• monitoring of symptoms and side effects
• ongoing clinician review

Because they share the same active ingredient, people often ask about the same practical issues with both products: appetite changes, nausea, bowel-pattern changes, dose escalation, and weekly injection technique.

Key differences: Alterme vs Ozempic

1. Brand and manufacturer

• Ozempic is made by Novo Nordisk.
• Alterme is associated with Zydus in India.

This changes the commercial brand, device ecosystem, and local access pathway, even though semaglutide remains the core medicine.

2. Market context in India

Ozempic is the internationally established originator brand. Alterme is part of the newer India-market semaglutide rollout following patent-expiry changes and local launches.

For patients, that may affect:

• which brands a pharmacy can source
• which pen design they receive
• pricing and refill patterns
• what their clinician is most comfortable prescribing

3. Delivery system

Ozempic is known for its branded pen device. Zydus described its semaglutide launch as using a reusable pen approach for brands including Alterme. Even when the active drug is the same, the injection experience and replacement process may differ.

4. Evidence and reference data

Most of the large, widely cited semaglutide trial data come from the originator semaglutide evidence base that is commonly associated with Ozempic and related semaglutide programs. When discussing Alterme, clinicians will still rely heavily on semaglutide class evidence, while also considering the locally marketed product and regulatory pathway.

Side effects and safety

Because both products are semaglutide-based, the expected side-effect pattern is broadly similar. Common effects can include:

• nausea
• vomiting
• diarrhoea
• constipation
• abdominal discomfort
• reduced appetite

Side effects are often more noticeable when starting treatment or increasing the dose. Your doctor may recommend a gradual titration plan to improve tolerability.

How to choose between them

The best option is not something to decide from brand recognition alone. A clinician may weigh:

• your diagnosis and treatment goals
• your previous response to GLP-1 therapy
• pen preference and comfort with injection technique
• availability in your local pharmacy
• overall treatment cost and follow-up needs

If you are unsure whether a prescription is for Ozempic or a newer semaglutide brand such as Alterme, ask your clinician to write down the exact brand name, dose, and weekly schedule.

Bottom line

Alterme and Ozempic are best understood as semaglutide-based options, not as completely different medication classes. The key difference is brand/manufacturer context—Zydus for Alterme in India versus Novo Nordisk for Ozempic—while the underlying drug mechanism remains centered on semaglutide.

A conversation with your clinician is the safest way to compare access, dosing, and suitability for your situation. Consult your healthcare provider before starting any medication.

Sources

• https://www.zyduslife.com/investor/admin/uploads/21/83/Zydus-plans-to-launch-innovative-Semaglutide-Injection-in-India-on-Day-1-of-patent-expiry--expanding-patient-access-to-GLP-1-therapy.pdf
• https://www.novo-pi.com/ozempic.pdf
• https://cdsco.gov.in/opencms/opencms/en/Home/
• https://www.nejm.org/doi/full/10.1056/NEJMoa2032183